'Variants identified in tumors can be germline – when to refer for germline testing' - ERN Genturis seminar
ERN Genturis (European Reference Network voor Genetic Tumor Risk syndromes) seminar by CRIG group leader prof. Kathleen Claes.
Since the number of druggable tumour-specific molecular aberrations has grown substantially in the past decade, tumour molecular profiling has been introduced at a large scale and revolutionized the field of precision oncology. Besides variants driving therapeutic decisions, germline variants are being detected, with implications for both the patient and relatives.
During the webinar an overview will be provided of the most relevant genes included in many cancer gene panels. Additionally, the prevalence of germline variants in different tumour types and issues on clonal hematopoiesis and mosaicism will be discussed and case-illustrated.
- Target audience: clinicians, genetic counsellors, clinical scientists and other genetics health professionals. The presentation itself lasts approximately 20-30 minutes, and viewers have the opportunity to send questions on the subject area which will be addressed in a question & answer session afterwards.
- Read more
- Registration